390 related articles for article (PubMed ID: 11698275)
21. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
22. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A
Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970
[TBL] [Abstract][Full Text] [Related]
23. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
24. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
25. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
26. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
27. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
28. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
29. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
30. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
31. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
[TBL] [Abstract][Full Text] [Related]
32. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Kohrt HE; Turnbull BB; Heydari K; Shizuru JA; Laport GG; Miklos DB; Johnston LJ; Arai S; Weng WK; Hoppe RT; Lavori PW; Blume KG; Negrin RS; Strober S; Lowsky R
Blood; 2009 Jul; 114(5):1099-109. PubMed ID: 19423725
[TBL] [Abstract][Full Text] [Related]
33. [Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors].
Yagasaki H; Kojima S; Inaba J; Kato K; Matsuyama T
Rinsho Ketsueki; 1999 May; 40(5):382-9. PubMed ID: 10390886
[TBL] [Abstract][Full Text] [Related]
34. Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies.
Dou L; Wang L; Li X; Liu Y; Li F; Wang L; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D
Medicine (Baltimore); 2021 Feb; 100(8):e24725. PubMed ID: 33663084
[TBL] [Abstract][Full Text] [Related]
35. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
[TBL] [Abstract][Full Text] [Related]
36. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG).
Bacigalupo A; Oneto R; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Romagnani C; Bruno B; Van Lint MT; Frassoni F
Bone Marrow Transplant; 2001 Dec; 28(12):1093-6. PubMed ID: 11803348
[TBL] [Abstract][Full Text] [Related]
37. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
[TBL] [Abstract][Full Text] [Related]
38. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
Messina G; Giaccone L; Festuccia M; Irrera G; Scortechini I; Sorasio R; Gigli F; Passera R; Cavattoni I; Filippi AR; Schianca FC; Pini M; Risitano AM; Selleri C; Levis A; Mordini N; Gallamini A; Pastano R; Casini M; Aglietta M; Montanari M; Console G; Boccadoro M; Ricardi U; Bruno B;
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1600-7. PubMed ID: 22484666
[TBL] [Abstract][Full Text] [Related]
39. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
40. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
